At the news
? BULLISHIMPACT 7/10 6-K filed Jun 17, 2026 at 16:48 ET
Ascendis Pharma completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $187.5 million in cash to an undisclosed buyer. The PRV was awarded by the FDA upon approval of YUVIWEL (navepegritide) in February 2026. This non-dilutive cash infusion provides a significant capital boost for the company's operations.
- Sale of Rare Pediatric Disease Priority Review Voucher (PRV) completed on June 17, 2026
- Proceeds of $187.5 million in cash, before transaction-related expenses
- PRV was awarded by FDA upon approval of YUVIWEL (navepegritide) in February 2026
- Buyer is undisclosed
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access